Comparison of ipratropium bromide and salbutamol by aerosolized solution
Jenkins, C.R.; Chow, C.M.; Fisher, B.L.; Marlin, G.E.
Australian and New Zealand Journal of Medicine 11(5): 513-516
1981
ISSN/ISBN: 0004-8291 PMID: 6459776 Document Number: 169976
Ipratropium bromide (0.125, 0.25 and 0.5 mg) and salbutamol (5 mg) by aerosolized solution produced equivalent peak bronchodilatation between 1 and 2 h after administration to 10 patients with chronic partially reversible airways obstruction. The duration of action of the 2 higher doses of ipratropium bromide (0.25 mg, 6 h; 0.5 mg, 5 h) was significantly greater than salbutamol (4 h). FVC increases which may indicate dilatation of small peripheral airways or removal of bronchial mucus from these sites after coughing. A dose of 0.25 mg ipratropium bromide as an aerosolized solution is recommended for clinical use.